Andre Manfred Willasch on Muck Rack

Andre Manfred Willasch

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andre Manfred

Contact Andre Manfred, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP | Bone Marrow Transplantation

|
By Claire Horgan, Christina Peters, Adriana Balduzzi, Marco Zecca, Ali Al-Ahmari, Franco Locatelli, Maura Faraci, Gerard Michel, Franca Fagioli, Alessandra Biffi, Fanny Rialland, Katharina Kleinschmidt, Maud Ngoya, Jacques-Emmanuel Galimard, Andre Manfred Willasch
| Nature Verified
Abstract Allogeneic haematopoietic stem cell transplantation (HSCT) is an essential treatment component for high-risk paediatric acute myeloid leukaemia (AML), but the choice of the optimal conditioning regimen remains controversial. We compared outcomes of two widely used myeloablative regimens, BuCy (Busulfan, Cyclophosphamide) versus BuCyMel (Busulfan, Cyclophosphamide, Melphalan) in children aged under 2 years undergoing HSCT in 1st complete remission (CR1).
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified